Search research articles

お問い合わせ

JoVEについて

概要リーダーシップブログ JoVEヘルプセンター

著者向け

出版プロセス編集委員会範囲と方針査読よくある質問投稿

図書館員向け

推薦の声購読アクセスリソース図書館諮問委員会よくある質問

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments アーカイブ

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教員リソースセンター教員サイト

プライバシーポリシー

関連する概念動画

Disorders of the Female Reproductive System

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え

Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026

Same author

No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

NPJ precision oncology·2026

Same author

Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellows.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Same author

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.

British journal of cancer·2026

Same author

Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era.

NPJ genomic medicine·2026

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連記事をすべて見る

Search research articles

関連する実験動画

Updated: Apr 4, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

子宮内膜がん

Philippe Morice¹, Alexandra Leary², Carien Creutzberg³

¹Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France; Unit INSERM U 1030, Gustave Roussy, Villejuif, France; Université Paris-Sud (Paris XI), Le Kremlin Bicêtre, France.

Lancet (London, England)

|September 11, 2015

まとめ

この要約は機械生成です。

子宮内膜がん,主に子宮内膜腺がんは,ますます早期に診断されています. 標準的な治療は子宮切除で患者と病気の要因に合わせて手術と補助療法を行います

さらに関連する動画

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

関連する実験動画

Last Updated: Apr 4, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

科学分野:

婦人科腫瘍学
手術腫瘍学
病理学について

背景:

子宮内膜がんは,先進国において最も一般的な婦人科悪性腫瘍であり,発生率は上昇しています.
エンドメトリオイド腺がんのサブタイプが最も一般的で,しばしば子宮に限定された初期段階で診断されます.

研究の目的:

子宮内膜がんの現在の標準治療戦略を概説する.
手術の決定と補助療法の選択に影響を与える要因について議論する.
高リスク患者に対する予後指標と進行中の研究を見直す.

主な方法:

主要な治療は,双方のサルピング・オオフォレクトミーによる子宮切除で,しばしば最小侵襲的外科技術を使用します.
リンパ節の管理は,組織学的特徴,疾患の段階,患者の特徴,および臨床ガイドラインによって導かれます.
補助療法は,再発リスクを管理するために,腫瘍組織学とステージに基づいて個別化されます.

主要な成果:

転移性疾患のない患者の5年生存率は74%から91%まで良好です.
手術後の管理と再発の予測に役立ちます.
進行中の臨床試験では,化学療法,化学放射線治療,高リスク集団のための標的治療などの新しい補助治療法を評価しています.

結論:

現在進行中の子宮内膜がんの治療は手術による介入と適合した補助策をバランスとしています
個別化された治療アプローチは,生存結果を最適化し,生活の質に悪影響を最小限に抑えることを目的としています.
高いリスクの子宮内膜がん患者の治療プロトコルの改善には,さらなる研究が不可欠です.